AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage ...

Pascal Soriot (pictured) said innovation in pharma 'has mostly been funded by the US' as he doubled down on plans to grow the ...

AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending ...

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

AstraZeneca CEO Pascal Soriot has urged European governments to increase investment in pharmaceutical innovation, warning of a growing imbalance between the US and Europe, which could threaten the ...

"Our company is firmly committed to investing and growing in the US," chief executive Pascal Soriot said in an earnings statement, which also reported that first-quarter profit rose by over 30 ...

Chief executive Pascal Soriot said the company continues to benefit from its “broad-based source of revenue and global manufacturing footprint”, including 11 production sites in the US.

Find insight on AstraZeneca, Hartalega and more in the latest Market Talks covering the health care sector.

Pascal Soriot said innovation in pharmaceuticals ‘has mostly been funded by the US’ as he doubled down on plans to grow the business in America – which already accounts for 40 per cent of ...

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the ...